The DOI matches its Crossref record.
1339P Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Open accessOverview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Non-G12C KRAS mutant NSCLC tumors differ from KRASG12C-mutated lung cancers in co-mutation of tumor suppressor genes.
“Non-G12C KRAS mutant NSCLC tumors are distinct from KRASG12C-mutated lung cancers in terms of co-mutation of tumor suppressor genes.”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [67]
TP53 co-mutation frequency is comparable in non-G12C KRAS-mutated NSCLC (32-35%), while STK11 (G12C 23%, G12D 14%) and KEAP1 (G12C 8%, G12D 4%) differ.
“While the frequency of TP53 co-occurring mutations is comparable in non-G12C-KRAS mutated NSCLC (32%−35%), differences can be observed for the tumor suppressors STK11 (co-mutation rates: G12C, 23%; G12D, 14%) and KEAP1 (co-mutation rates: G12C, 8%; G12D, 4%).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [67]
Citations
Cited by
Sorted by citations
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Metadata
- Authors
- Aggarwal, S., Whipple, S., Hsu, H., Tu, H., Carrigan, G., Wang, X., Ngarmchamnanrith, G., & Chia, V.
- Affiliations
- Amgen (United States) (US)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 31
- Pages
- S860
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3088066047
- Cited by
- 8
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- KRAS G12C mutation, non-small cell lung cancer, lung adenocarcinoma, clinicopathological features, treatment patterns, real-world evidence, Flatiron Health, Foundation Medicine, targeted therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
